Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totalling 236,400 shares, a decrease of 9.6% from the March 15th total of 261,500 shares. Based on an average daily volume of 88,300 shares, the days-to-cover ratio is presently 2.7 days.

Enlivex Therapeutics Stock Performance

NASDAQ ENLV traded up $0.03 on Wednesday, hitting $1.48. The stock had a trading volume of 388,662 shares, compared to its average volume of 167,805. Enlivex Therapeutics has a 52-week low of $1.15 and a 52-week high of $4.59. The firm has a 50-day moving average of $3.41 and a 200-day moving average of $2.55.

Institutional Trading of Enlivex Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in ENLV. Jane Street Group LLC raised its position in shares of Enlivex Therapeutics by 89.6% during the 1st quarter. Jane Street Group LLC now owns 52,507 shares of the company’s stock valued at $294,000 after buying an additional 24,807 shares in the last quarter. UBS Group AG raised its position in shares of Enlivex Therapeutics by 73.4% during the 3rd quarter. UBS Group AG now owns 31,871 shares of the company’s stock valued at $136,000 after buying an additional 13,490 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Enlivex Therapeutics during the 1st quarter valued at $68,000. Finally, Bank of America Corp DE raised its position in shares of Enlivex Therapeutics by 87.0% during the 1st quarter. Bank of America Corp DE now owns 6,163 shares of the company’s stock valued at $34,000 after buying an additional 2,867 shares in the last quarter. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their target price on shares of Enlivex Therapeutics from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, April 12th.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.